Analgesic application of a novel non-steroidal anti-inflammatory drug imrecoxib after total knee arthroplasty: a prospective randomized controlled study
Authors' conclusion
Our prospective randomized controlled trial demonstrates that imrecoxib can effectively alleviate postoperative pain after TKA, reduce opioid dosage, and does not cause additional adverse reactions
Study context
- Population
- Patients undergoing total knee arthroplasty (TKA)
- Participants
- 120 patients
- Comparison
- Imrecoxib plus conventional treatment vs conventional treatment alone
Methodological detailsprospective
- Prospective
Further findings
| Outcome | Experimental | Control | P value |
|---|---|---|---|
| VAS pain score at movement (four postoperative time points)First time point · lower in the experimental group at all four time points | 4.050 (SD 0.805) | 4.433 (SD 0.782) | P = 0.013 |
| VAS pain score at movement (four postoperative time points)Second time point · lower in the experimental group at all four time points | P = 0.027 | ||
| VAS pain score at movement (four postoperative time points)Third time point · lower in the experimental group at all four time points | P = 0.000 | ||
| VAS pain score at movement (four postoperative time points)Fourth time point · lower in the experimental group at all four time points | P = 0.000 | ||
| Joint ROM · 24 h | 84.783 (SD 7.902) | 76.725 (SD 9.499) | P = 0.000 |
| Joint ROM · 48 h | 86.403 (SD 10.367) | 79.802 (SD 8.400) | P = 0.000 |
| Postoperative opioid consumption | 0.567 (SD 0.692) | 2.783 (SD 1.156) | P = 0.000 |
- Visual analogue scale (VAS) pain score at movement (four postoperative time points): Experimental 4.633 (SD 1.048)
- VAS pain score at movement (four postoperative time points): Experimental 4.517 (SD 1.057)
- VAS pain score at movement (four postoperative time points): Experimental 4.233 (SD 0.844)
- VAS pain score at movement (four postoperative time points): Control 5.067 (SD 0.910)
- VAS pain score at movement (four postoperative time points): Control 5.800 (SD 0.945)
- VAS pain score at movement (four postoperative time points): Control 5.167 (SD 1.003)
Safety
- Imrecoxib did not cause additional adverse reactions
Original publication
Analgesic application of a novel non-steroidal anti-inflammatory drug imrecoxib after total knee arthroplasty: a prospective randomized controlled study. Perioper Med (Lond). Published 15 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →